公开(公告)号：US09289383B2

公开(公告)日：2016-03-22

申请号：US14552160

申请日：2014-11-24

申请人： Inotek Pharmaceuticals Corporation

发明人： Norman N. Kim ,  William K. McVicar ,  Thomas G. McCauley ,  Prakash Jagtap

IPC分类号： A61K31/70 ,  A61K9/00 ,  A61K31/495 ,  A61K31/7076 ,  C07H19/167 ,  A61K45/06 ,  C07H19/16

CPC分类号： A61K31/7076 ,  A61K9/0048 ,  A61K31/495 ,  A61K45/06 ,  C07H19/16 ,  C07H19/167

摘要： Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).

公开(公告)号：US08895530B2

公开(公告)日：2014-11-25

申请号：US13909288

申请日：2013-06-04

申请人： Inotek Pharmaceuticals Corporation

发明人： Norman N. Kim ,  William K. McVicar ,  Thomas G. McCauley ,  Prakash Jagtap

IPC分类号： A61K31/70 ,  C07H19/167 ,  A61K31/7076 ,  A61K31/495

CPC分类号： A61K31/7076 ,  A61K9/0048 ,  A61K31/495 ,  A61K45/06 ,  C07H19/16 ,  C07H19/167

摘要： Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).

摘要翻译： 本文提供了使用N6-环戊基腺苷（CPA），CPA衍生物或前药或CPA增强的角膜通透性制剂降低人眼内压（IOP）的方法。 在一个实施方案中，本发明涉及可透过角膜的CPA衍生物或前药。 在另一个实施方案中，本发明涉及某些化合物在人受试者中用于减少和/或控制治疗青光眼或高眼压症（OHT）的升高或异常波动的IOP的用途。